Otsuka is buying neuropsychiatric drugmaker Transcend Therapeutics in a deal worth roughly $1.2 billion, further bolstering a class of drugs that are supposed to provide

Plus, news about Zenas and Ysios Capital: 🌀 AnaptysBio’s spinout: The independent public company, called First Tracks Biotherapeutics, is expected to start trading on April

A rare disease gene therapy from Rocket Pharmaceuticals has garnered FDA approval after an earlier rejection for manufacturing problems. The FDA on Thursday granted accelerated

The FDA finally greenlit Novo Nordisk’s once-weekly insulin for type 2 diabetes, making it the first US-approved longer-acting alternative to daily basal treatment for this

Recordati has received a takeover offer from private equity group CVC that, if completed, would delist it from the Italian stock exchange.